UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Author | Type
Jump to: A | B | C | D | F | G | H | K | L | M | N | O | P | R | S | T | V | W | Y
Number of items: 101.


Alliouachene, S; Tuttle, RL; Boumard, S; Lapointe, T; Berissi, S; Germain, S; Jaubert, F; ... Pende, M; + view all (2008) Constitutively active Akt1 expression in mouse pancreas requires S6 kinase 1 for insulinoma formation. J Clin Invest , 118 (11) pp. 3629-3638. 10.1172/JCI35237.

Alonso, S; Lopez, S; Izagirre, N; de la Rua, C; (2008) Overdominance in the Human Genome and Olfactory Receptor Activity. Molecular Biology and Evolution , 25 (5) pp. 997-1001. 10.1093/molbev/msn049.

Alonzi, R.; (2008) Evaluation of the oxygenation and vascularity of prostate cancer using magnetic resonance imaging. Doctoral thesis , University of London. Green open access

Arkenau, H; Barrius, J; Olmos, D; Ang, JE; De Bono, J; Judson, I; Kaye, SB; (2008) Prospective validation of a prognostic score to improve patient selection for phase-1 trials. In: ANNALS OF ONCOLOGY. (pp. 145 - 145). OXFORD UNIV PRESS

Arkenau, H-T; Arnold, D; Cassidy, J; Diaz-Rubio, E; Douillard, J-Y; Hochster, H; Martoni, A; ... Porschen, R; + view all (2008) Efficacy of Oxaliplatin Plus Capecitabine or Infusional Fluorouracil/Leucovorin in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Randomized Trials. JOURNAL OF CLINICAL ONCOLOGY , 26 (36) pp. 5910-5917. 10.1200/JCO.2008.16.7759.

Arkenau, HT; Carden, CP; de Bono, JS; (2008) Targeted agents in cancer therapy. Medicine , 36 (1) pp. 33-37. 10.1016/j.mpmed.2007.10.007.

Arkenau, HT; Porschen, R; (2008) The combination of oxaliplatin with either capecitabine or infusional 5-fluorouracil/leucovorin results in comparable outcome in patients with metastatic colorectal cancer. American Journal of Hematology/ Oncology , 7 (1) pp. 35-37.


Barriuso, J; Arkenau, HT; Olmos, D; Ang, J; Brunetto, A; Frentzas, S; Ayite, B; ... Kaye, S; + view all (2008) PROSPECTIVE VALIDATION OF A PROGNOSTIC SCORE FOR PATIENTS TREATED IN PHASE-I TRIALS. In: (Proceedings) 33rd Congress of the European-Society-for-Medical-Oncology (ESMO). (pp. p. 164). OXFORD UNIV PRESS

Ben-Smith, A; Gorak-Stolinska, P; Floyd, S; Weir, RE; Lalor, MK; Mvula, H; Crampin, AC; ... Dockrell, HM; + view all (2008) Differences between naive and memory T cell phenotype in Malawian and UK adolescents: a role for Cytomegalovirus? BMC Infectious Diseases , 8 , Article 139. 10.1186/1471-2334-8-139. Green open access

Besana, P; Patkar, V; Glasspool, D; Robertson, D; (2008) Distributed Workflows: The OpenKnowledge Experience. In: Meersman, R and Tari, Z and Herrero, P, (eds.) ON THE MOVE TO MEANINGFUL INTERNET SYSTEMS: OTM 2008 WORKSHOPS. (pp. 965 - 975). SPRINGER-VERLAG BERLIN

Bhatti, M; Yahioglu, G; Milgrom, LR; Garcia-Maya, M; Chester, KA; Deonarain, MP; (2008) Targeted photodynamic therapy with multiply-loaded recombinant antibody fragments. INT J CANCER , 122 (5) 1155 - 1163. 10.1002/ijc.23206.

Bielack, S; Marina, N; Ferrari, S; Helman, LH; Smeland, S; Whelan, JS; Reaman, GH; (2008) Response to Meyers et al, Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival- a report from the Children's Oncology Group (letter0. Journal of Clinical Oncology , 4 pp. 633-638.

Bilanges, B; Torbett, N; Vanhaesebroeck, B; (2008) Killing two kinase families with one stone. NATURE CHEMICAL BIOLOGY , 4 (11) pp. 648-649. 10.1038/nchembio1108-648.

Booth, CM; Calvert, AH; Giaccone, G; Lobbezoo, MW; Eisenhauer, EA; Seymour, LK; Task Force Methodology Dev Innovat, ; (2008) Design and conduct of phase II studies of targeted anticancer therapy: Recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT). EUR J CANCER , 44 (1) 25 - 29. 10.1016/j.ejca.2007.07.031.

Brown, T; Mackay, H; Turlington, M; Sutterfield, A; Smith, T; Sielaff, A; Westrate, L; ... and Lee, M; + view all (2008) Modifying the N-Terminus of Polyamides: PyImPyIm has Improved Sequence Specificity over f-ImPyIm. Bioorganic and Medicinal Chemistry , 16 pp. 5266-5276.

Buchler, T; Dubash, S; Lee, V; Chilton, D; Cartledge, J; Isaacson, P; Tedder, RS; (2008) Rituximab failure in fulminant multicentric HIV/human herpesvirus 8-associated Castlemans disease with multiorgan failure: Report of two cases. AIDS , 22 (13) pp. 1685-1687. 10.1097/QAD.0b013e3282f7371f.


Calvert, AH; Plummer, R; (2008) The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials. CLIN CANCER RES , 14 (12) 3664 - 3669. 10.1158/1078-0432.CCR-07-4559.

Calvert, H; Plummer, ER; Curtin, NJ; Edmondson, R; Drew, Y; (2008) PARP inhibitors in cancer treatment. In: EJC SUPPLEMENTS. (pp. 80 - 80). PERGAMON-ELSEVIER SCIENCE LTD

Cassoni, A; Ali, U; Cave, J; Edwards, SG; Ramsay, A; Miller, RF; Lee, SM; (2008) Remission After Radiotherapy for a Patient With Chemotherapy-Refractory HIV-Associated Primary Effusion Lymphoma. J CLIN ONCOL , 26 (32) 5297 - 5299. 10.1200/JCO.2008.18.3350.

Cassoni, A; Ali, U; Cave, J; Edwards, SG; Ramsay, A; Miller, RF; Siow, ML; (2008) Remission after radiotherapy for a patient with chemotherapy-refractory HIV-associated primary effusion lymphoma. Journal of Clinical Oncology , 26 (32) pp. 5297-5299. 10.1200/JCO.2008.18.3350.

Chen, Y-C; Chiang, H-Y; Yang, M-H; Chen, P-M; Chang, S-Y; Teng, S-C; Vanhaesebroeck, B; (2008) Activation of phosphoinositide 3-kinase by the NBS1 DNA repair protein through a novel activation motif. JOURNAL OF MOLECULAR MEDICINE-JMM , 86 (4) pp. 401-412. 10.1007/s00109-008-0302-x.

Chung, Y-L; Troy, H; Kristeleit, R; Aherne, W; Jackson, LE; Atadja, P; Griffiths, JR; ... Beloueche-Babari, M; + view all (2008) Noninvasive magnetic resonance spectroscopic pharmacodynamic markers of a novel histone deacetylase inhibitor, LAQ824, in human colon carcinoma cells and xenografts. Neoplasia , 10 (4) pp. 303-313. Gold open access

Clingen, PH; Wu, JYH; Miller, J; Mistry, N; Chin, F; Wynne, P; Prise, KM; (2008) Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. BIOCHEM PHARMACOL , 76 (1) 19 - 27. 10.1016/j.bcp.2008.03.025.

Cuenca, F; Greciano, O; Gunaratnam, M; Haider, S; Munnur, D; Nanjunda, R; Wilson, WD; (2008) Tri- and tetra-substituted naphthalene diimides as potent G-quadruplex ligands. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS , 18 (5) pp. 1668-1673. 10.1016/j.bmcl.2008.01.050.


Drew, Y; Calvert, H; (2008) The Potential of PARP Inhibitors in Genetic Breast and Ovarian Cancers. RECENT ADVANCES IN CLINICAL ONCOLOGY , 1138 136 - 145. 10.1196/annals.1414.020.

Drewe, WC; Nanjunda, R; Gunaratnam, M; Beltran, M; Parkinson, GN; Reszka, AP; Wilson, WD; (2008) Rational Design of Substituted Diarylureas: A Scaffold for Binding to G-Quadruplex Motifs. JOURNAL OF MEDICINAL CHEMISTRY , 51 (24) pp. 7751-7767. 10.1021/jm801245v.

de Bruin, EC; Medema, JP; (2008) Apoptosis and non-apoptotic deaths in cancer development and treatment response. Cancer Treat Rev , 34 (8) pp. 737-749. 10.1016/j.ctrv.2008.07.001.


Fern, L; Campbell, C; Eden, T; Grant, R; lewis, I; McCleod, U; Weller, D; ... J, ; + view all (2008) Addressing delayed cancer diagnosis in primary care: Patterns of attendance and symptoms of teenagers and young adults seen in 3 general practices during 1 year. In:

Fidarova, EF; El-Emir, E; Boxer, GM; Qureshi, U; Dearling, JLJ; Robson, MP; Begent, RHJ; ... Pedley, RB; + view all (2008) Microdistribution of targeted, fluorescently labeled anti carcinoembryonic antigen antibody in metastatic colorectal cancer: Implications for radioimmunotherapy. CLIN CANCER RES , 14 (9) 2639 - 2646. 10.1158/1078-0432.CCR-07-2031.

Folarin, A.A.; (2008) Analysis of tumour angio-architecture and blood flow using microcomputed tomography and lattice Boltzmann simulations. Doctoral thesis , University of London. Green open access

Fox, J; Black, E; Chronakis, I; Dunlop, R; Patkar, V; South, M; Thomson, R; (2008) From guidelines to careflows: modelling and supporting complex clinical processes. Stud Health Technol Inform , 139 pp. 44-62.


Gaya, AM; Violet, J; Dancey, G; Green, A; Stratford, M; Sharma, S; Owen, K; ... Meyer, T; + view all (2008) A phase I/II trial of radioimmunotherapy with (131)Iodine labelled A5B7 anti-CEA antibody (I-131-A5B7) in combination with Combretastatin-A4-Phosphate (CA4P) in advanced gastrointestinal carcinomas. In: AMER SOC CLINICAL ONCOLOGY

Gelderblom, H; Sydes, MR; Morgan, RC; Hogendoorn, PC; Lewis, IJ; Nooij, MA; Taminiau, AH; (2008) Survival after recurrent osteosarcoma: Data from three European Osteosarcoma Intergroup (EOI) randomized controlled. Presented at: UNSPECIFIED.

Giampieri, S; Sahai, E; (2008) Activation of TGF-beta signalling in breast cancer metastatic cells. In: BREAST CANCER RESEARCH. (pp. S3 - S4). BIOMED CENTRAL LTD

Gillmore, R; Laurence, V; Paisey, S; Mukherjee, S; Hudson, E; Raouf, S; Collis, C; ... Bridgewater, J; + view all (2008) The role of chemoradiotherapy in sub-optimally resectable locally advanced adenocarcinoma of the pancreas. In: AMER SOC CLINICAL ONCOLOGY

Graham, JS; Plummer, R; McCoy, C; Kowal, K; Wiesinger, H; Detjen, K; Calvert, H; ... Cassidy, J; + view all (2008) Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery). EUR J CANCER , 44 (15) 2162 - 2168. 10.1016/j.ejca.2008.06.006.

Green, AJ; Francis, RJ; Baig, S; Begent, RHJ; (2008) Semiautomatic volume of interest drawing for F-18-FDG image analysis - method and preliminary results. EUR J NUCL MED MOL I , 35 (2) 393 - 406. 10.1007/s00259-007-0602-3.

Guo, H; Samarakoon, A; Vanhaesebroeck, B; Malarkannan, S; (2008) The p110 delta of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation. JOURNAL OF EXPERIMENTAL MEDICINE , 205 (10) pp. 2419-2435. 10.1084/jem.20072327.


Harrison, M; Swanton, C; (2008) Epothilones and new analogues of the microtubule modulators in taxane-resistant disease. Expert Opin Investig Drugs , 17 (4) pp. 523-546. 10.1517/13543784.17.4.523.

Hazrati, A; Ramis-Castelitort, M; Sarkar, S; Barber, LJ; Schofield, CJ; Hartley, JA; McHugh, PJ; (2008) Human SNM1A suppresses the DNA repair defects of yeast pso2 mutants. DNA REPAIR , 7 (2) 230 - 238. 10.1016/j.dnarep.2007.09.013.

Hiwarkar, P; Arkenau, HT; Treleaven, J; Morgan, G; Potter, M; Ethell, M; (2008) The feasibility of using topotecan, vinorelbine, thiotepa and gemcitabine (TVTG) in adult patients with relapsed/refractory acute lymphoblastic leukaemia/lymphoma. LEUKEMIA , 22 (8) 1627 - 1629. 10.1038/leu.2008.31.

Hochhauser, D; Meyer, T; Loadman, P; Spanswick, VJ; Cobb, M; Begent, RH; Wu, J; ... Jodrell, D; + view all (2008) Phase I study of the DNA minor groove binding pyrrolobenzodiazepine dimer (SJG 136) administered every 21 days in patients with advanced solid tumours. In: AMER SOC CLINICAL ONCOLOGY

Howie, AJ; (2008) Handbook of renal biopsy pathology. [Book]. (2nd ed. ed.). Springer: New York, USA.

Howie, AJ; Agarwal, A; Sebire, NJ; Trompeter, RS; (2008) Glomerular tip changes in childhood minimal change nephropathy. PEDIATR NEPHROL , 23 (8) 1281 - 1286. 10.1007/s00467-008-0823-0.

Howie, AJ; Brewer, DB; Howell, D; Jones, AP; (2008) Physical basis of colors seen in Congo red-stained amyloid in polarized light. LAB INVEST , 88 (3) 232 - 242. 10.1038/labinvest.3700714.


Kanu, N; Behrens, A; (2008) ATMINistrating ATM signalling: regulation of ATM by ATMIN. Cell Cycle , 7 (22) pp. 3483-3486. 10.4161/cc.7.22.7044.

Karavasilis, V; Digue, L; Arkenau, T; Eaton, D; Stapleton, S; de Bono, J; Judson, I; (2008) Identification of factors limiting patient recruitment into phase I trials: A study from the Royal Marsden Hospital. EUROPEAN JOURNAL OF CANCER , 44 (7) pp. 978-982. 10.1016/j.ejca.2008.02.040.

Kogelberg, H; Tolner, B; Thomas, GJ; Di Cara, D; Minogue, S; Ramesh, B; Sodha, S; ... Chester, K; + view all (2008) Engineering a single-chain Fv antibody to alpha v beta 6 integrin using the specificity-determining loop of a foot-and-mouth disease virus. JOURNAL OF MOLECULAR BIOLOGY , 382 (2) pp. 385-401. 10.1016/j.jmb.2008.07.013.


Lee, SM; Brada, M; Stenning, S; Thompson, L; (2008) A randomised trial of Procarbazine, CCNU and Vincristine (PCV) vs Temozolomide (5-day or 21-day schedule) for recurrent high grade glioma (MRC BR12, ISRCTN83176944). In: (Proceedings) Presidential Symposium. 33rd ESMO Congress Stockholm, Sweden.

Lee, SM; James, L; Buchler, T; Snee, M; Ellis, P; Hackshaw, A; (2008) Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. Lung Cancer , 59 (3) pp. 364-368.

Lee, SM; James, L; Buchler, T; Snee, M; Ellis, P; Hackshaw, A; (2008) Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. Lung Cancer , 59 (3) pp. 364-368. 10.1016/j.lungcan.2007.08.032.

Lee, SM; Rudd, RM; Woll, PJ; Ottensmeier, CH; James, LE; Gower, NH; Spiro, SG; ... Hackshaw, A; + view all (2008) Two randomised phase III, double blind, placebo controlled trials of thalidomide in patients with advanced non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). In: (Proceedings) 2008 ASCO Annual Meeting Proceedings, Chicago, IL. (pp. 435s-). Journal of Clinical Oncology


Marina, N; Bielack, ; S, ; Whelan, JS; Smeland, S; Krailo, M; Sydes, M; ... Bernstein, M; + view all (2008) UNSPECIFIED In: (Proceedings) International collaboration is feasible for trials in rare conditions: the EURAMOS experience. Meeting Proceedings - Paediatric and Adolescent Osteosarcoma. Progress from the past, prospects for the future.. : Houston.

Matthews, DR; Ameer-Beg, SM; Barber, P; Pierce, GP; Newman, RG; Vojnovic, B; Carlin, LM; ... Irving, M; + view all (2008) A high-content screening platform utilizing polarization anisotropy and FLIM microscopy. Progress in Biomedical Optics and Imaging - Proceedings of SPIE , 6859 10.1117/12.763310.

McTiernan, A; Morgan, R; Sydes, MR; Uscinska, B; van, GM; Bramwell, V; Souhami, RL; ... Whelan, JS; + view all (2008) The more it hurts, the better it works? Chemotherapy toxicity as a predictor of outcome from osteosarcoma: a report from the European Osteosarcoma Intergroup. In:

Meyer, T; Caplin, M; Palmer, D; Valle, JW; Larvin, M; Waters, J; Coxon, F; ... Kato, H; + view all (2008) A phase IB/IIA, multicentre, randomised, double-blind placebo controlled study to evaluate the safety and pharmacokinetics of Z-360 in subjects with unresectable advanced pancreatic cancer in combination with gemcitabine. JOURNAL OF CLINICAL ONCOLOGY , 26 (15)

Monahan, KJ; Carvajal-Carmona, L; Thirlwell, C; Thomas, HJW; Tomlinson, IP; (2008) Identification of genetic variation in dut, a potential colorectal tumour suppressor gene. In: GUT. (pp. A138 - A138). B M J PUBLISHING GROUP

Muller, CI; Schulmann, K; Reinacher-Schick, A; Andre, N; Arnold, D; Tannapfel, A; Arkenau, H; ... Graeven, U; + view all (2008) Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. INT J COLORECTAL DIS , 23 (11) 1033 - 1039. 10.1007/s00384-008-0504-2.


Ng, Q.S.; (2008) Therapeutic targeting and clinical assessment of the tumour vasculature. Doctoral thesis , University of London. Green open access


Olmos, D; Arkenau, H-T; Ang, JE; de Bono, JS; Judson, I; Kaye, SB; (2008) Reply: Clinical outcome and prognostic factors for patients treated within a phase I study: the Royal Marsden Hospital Experience. BRITISH JOURNAL OF CANCER , 99 (8) p. 1365. 10.1038/sj.bjc.6604649.

Olmos, D; Swanton, C; de Bono, J; (2008) Targeting Polo-Like Kinase: Learning Too Little Too Late? JOURNAL OF CLINICAL ONCOLOGY , 26 (34) pp. 5497-5499. 10.1200/JCO.2008.18.6585.


Patkar, V; Fox, J; (2008) Clinical guidelines and care pathways: a case study applying PROforma decision support technology to the breast cancer care pathway. Stud Health Technol Inform , 139 pp. 233-242.

Patterson, DM; Murugaesu, N; Holden, L; Seckl, MJ; Rustin, GJS; (2008) A review of the close surveillance policy for stage I female germ cell tumors of the ovary and other sites. Int J Gynecol Cancer , 18 (1) pp. 43-50. 10.1111/j.1525-1438.2007.00969.x.

Paulussen, M; Craft, A; Lewis, I; Hackshaw, A; Douglas, C; Dunst, J; Schuck, A; ... Jurgens, HFTEICESSG; + view all (2008) Results of the EICESS-92 study: two randomised trials of Ewing's sarcoma treatment. Journal of Clinical Oncology , 20 pp. 4385-4393.

Pipinikas, CP; Carter, ND; Corbishley, CM; Fenske, CD; (2008) HIF-1 alpha mRNA gene expression levels in improved diagnosis of early stages of prostate cancer. BIOMARKERS , 13 (7-8) pp. 680-691. 10.1080/13547500802591992.

Popat, R; Maharaj, L; Oakervee, H; Cavenagh, J; Middleton, B; Rioja, A; Marson, C; (2008) THE NOVEL HDAC INHIBITOR UCL67022 HAS POTENT ACTIVITY IN MULTIPLE MYELOMA CELLS AND REMAINS EFFECTIVE IN A BONE MARROW MICRO-ENVIRONMENT MODEL. In: (Proceedings) 13th Congress of the European-Hematology-Association. (pp. p. 115). FERRATA STORTI FOUNDATION Gold open access

Postel-Vinay, S; Arkenau, HT; Olmos, D; Barriuso, J; Ashley, S; Ang, J; De Bono, J; ... Kaye, S; + view all (2008) Patient selection criteria for PHASE-I trials in oncology: Low lymphocyte counts are associated with poor survival. In: (Proceedings) 6th International Symposium on Target Anticancer Therapies. (pp. pp. 34-35). OXFORD UNIV PRESS

Puzanov, I; Lee, W; Berlin, JD; Calcutt, MW; Hachey, DL; Vermeulen, WL; Spanswick, VJ; ... Rothenberg, ML; + view all (2008) Final results of phase I and pharmacokinetic trial of SJG-136 administered on a daily x 3 schedule. In: AMER SOC CLINICAL ONCOLOGY


Ray-Coquard, I; Le, CA; Whelan, JS; Scoffski, P; Bui, BN; Verweij, J; van, GM; ... Blay, J-Y; + view all (2008) A phase II study of Gefitinib for patients with HER-1 expressing advanced synovial sarcoma refractory to doxorubicin-based chemotherapy. The Oncologist , 13 pp. 467-473.


Sarker, D; Anderson, D; Spanswick, VJ; Davies, S; Agarwal, R; Aitken, G; Kerr, DJ; ... Middleton, MR; + view all (2008) Preliminary results of a Cancer Research UK phase I trial combining the dinitrobenzamide prodrug CB1954 (tretazicar) and the NQO2 substrate EP-0152R (caricotamide). In: AMER SOC CLINICAL ONCOLOGY

See, TC; Thompson, BC; Howie, AJ; Karamshi, M; Papadopoulou, AM; Davies, N; Tibballs, J; (2008) Transjugular renal biopsy: Our experience and technical considerations. CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY , 31 (5) pp. 906-918. 10.1007/s00270-008-9308-6.

Shah, T; Kulakiene, I; Quigley, AM; Warbey, VS; Srirajaskanthan, R; Toumpanakis, C; Hochhauser, D; ... Caplin, ME; + view all (2008) The role of <sup>99m</sup>Tc-depreotide in the management of neuroendocrine tumours. Nuclear Medicine Communications , 29 (5) pp. 436-440.

Shah, T; Kulakiene, I; Quigley, AM; Warbey, VS; Srirajaskanthan, R; Tournpanakis, C; Hochhauser, D; ... Caplin, ME; + view all (2008) The role of Tc-99m-depreotide in the management of neuroendocrine tumours. NUCLEAR MEDICINE COMMUNICATIONS , 29 (5) 436 - 440.

Short, S; C, ; (2008) Survival from brain tumours in England and Wales up to 2001. British Journal of Cancer

Short, SC; Martindale, C; Worku, M; Bourne, S; (2008) THE INFLUENCE OF RAD51 MEDIATED REPAIR ON TREATMENT RESISTANCE IN HIGH-GRADE GLIOMAS. In: (Proceedings) 8th Congress of the European-Association-for-Neuro-Oncology (EANO). (pp. p. 1144). DUKE UNIV PRESS

Siddika, A; Jamal-Hanjani, M; Coker, JB; Ullah, MZ; (2008) Laparoscopy: a tool for the diagnosis and treatment of omental torsion. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE , 62 (11) pp. 1807-1808. 10.1111/j.1742-1241.2006.00900.x.

Sky, NO; (2008) EMEA Likely To Give Go Ahead On Thalidomide. UNSPECIFIED

Soria, SC; Plummer, R; Soto, A; Massard, C; Calvert, H; Prados, R; Angevin, E; ... de las Heras, B; + view all (2008) Phase I study of the novel anti-cancer drug PM00104 as a 1-hour weekly infusion resting every fourth week in patients with advanced solid tumors or lymphoma. In: EJC SUPPLEMENTS. (pp. 57 - 57). PERGAMON-ELSEVIER SCIENCE LTD

Speetjens, FM; de Bruin, EC; Morreau, H; Zeestraten, ECM; Putter, H; van Krieken, JH; van Buren, MM; ... Kuppen, PJK; + view all (2008) Clinical impact of HLA class I expression in rectal cancer. Cancer Immunol Immunother , 57 (5) pp. 601-609. 10.1007/s00262-007-0396-y.

Spratlin, J; Arkenau, HT; George, S; Serkova, NJ; Germuska, M; Brock, K; Gedrich, R; ... Camidge, DR; + view all (2008) Analyses of pharmacodynamic (PD) assessments collected during expanded cohorts (EC) of a phase I trial with OSI-930, a multi-targeted oral tyrosine kinase inhibitor (TKI). In: (Proceedings) 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. (pp. p. 19). PERGAMON-ELSEVIER SCIENCE LTD

Srirajaskanthan, R; Marelli, L; Mendes, N; Krepska, A; Davidson, A; Toumpanakis, C; Meyer, T; ... Caplin, M; + view all (2008) Diagnosis, management and survival of pancreatic endocrine tumours. In: (Proceedings) Annual General Meeting of the British-Society-of-Gastroenterology. (pp. A161-A161). B M J PUBLISHING GROUP

Srirajaskanthan, R; Shah, T; Bhogal, M; Toumpanakis, C; Meyer, T; Noonan, A; Amin, T; ... Hochhauser, D; + view all (2008) The role of alpha fetoprotein and human chorionic gonadotrophin-beta as prognostic tumour markers in patients with neuroendocrine tumours. In: GUT. (pp. A68 - A69). B M J PUBLISHING GROUP

Stebbing, J; Harrison, M; Glynne-Jones, R; Bridgewater, J; Propper, D; (2008) A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study). BRITISH JOURNAL OF CANCER , 98 (4) pp. 716-719. 10.1038/sj.bjc.6604232.

Swanton, C; Downward, J; (2008) Unraveling the complexity of endocrine resistance in breast cancer by functional genomics. CANCER CELL , 13 (2) pp. 83-85. 10.1016/j.ccr.2008.01.021.


Taylor, RE; Pizer, BL; Short, S; (2008) Promoting collaboration between adult and paediatric clinical trial groups. Clin Oncol (R Coll Radiol) , 20 (9) pp. 714-716. 10.1016/j.clon.2008.06.009.

Thirlwell, C; Nathan, P; (2008) Melanoma - Part 2: management. BRIT MED J , 337 , Article a2488. 10.1136/bmj.a2488.

Tiberghien, AC; Evans, DA; Kiakos, K; Martin, CRH; Hartley, JA; Thurston, DE; Howard, PW; (2008) An asymmetric C8/C8'-tripyrrole-llinked sequence-selective Pyrrolo[2,1-c]]1,4]benzodiazepine (PBD) dimer DNA interstrand cross-linking agent spanning 11 DNA base pairs. Bioorganic and Medicinal Chemistry Letters , 18 (6) pp. 2073-2077. 10.1016/j.bmcl.2008.01.096.


Vassileva, V; Allen, CJ; Piquette-Miller, M; (2008) Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. MOLECULAR CANCER THERAPEUTICS , 7 (3) pp. 630-637. 10.1158/1535-7163.MCT-07-2117.

Vassileva, V; Moriyama, EH; De Souza, R; Grant, J; Allen, CJ; Wilson, BC; Piquette-Miller, M; (2008) Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging. BRITISH JOURNAL OF CANCER , 99 (12) pp. 2037-2043. 10.1038/sj.bjc.6604803.

Vassileva, V; Piquette-Miller, M; (2008) Ovarian tumour repopulation in response to sustained and intermittent paclitaxel therapy. In: (Proceedings) 109th Annual Meeting of the American-Society-for-Clinical-Pharmacology-and-Therapeutics. (pp. S52-S52). NATURE PUBLISHING GROUP

Vassileva, VT; (2008) The Effects of Sustained and Intermittent Intraperitoneal Paclitaxel Chemotherapy on Tumour Repopulation and Response in Ovarian Cancer. Doctoral thesis , University of Toronto.

Vergote, IB; Calvert, H; Kania, M; Zimmerman, A; Look, K; Sehouli, J; (2008) A randomized phase II study of standard-versus high-dose pernetrexed in platinum-resistant epithellial ovarian cancer. GYNECOL ONCOL , 108 (3) S113 - S113.


Wang, M-L; Panasyuk, G; Gwalter, J; Nemazanyy, I; Fenton, T; Filonenko, V; Gout, I; (2008) Regulation of ribosomal protein S6 kinases by ubiquitination. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS , 369 (2) pp. 382-387. 10.1016/j.bbrc.2008.02.032.

Wells, G; Suggitt, M; Coffils, M; Baig, MAH; Howard, PW; Loadman, PM; Hartley, JA; ... Thurston, DE; + view all (2008) Fluorescent 7-diethylaminocoumarin pyrrolobenzodiazepine conjugates: Synthesis, DNA interaction, cytotoxicity and differential cellular localization. BIOORG MED CHEM LETT , 18 (6) 2147 - 2151. 10.1016/j.bmcl.2008.01.083.

Whelan, J; Fern, L; (2008) Keynote Comment: Poor rates of accrual of teenagers and young adults into clinical trials in the UK. The Lancet Oncology , 9 pp. 306-307.

Whelan, J; Fern, LA; (2008) Rates of inclusion of teenagers and young adults (TYA) with cancer into UK National Cancer Research Institute (NCRI) clinical trials, 2005-2007. In: AMER SOC CLINICAL ONCOLOGY

Whelan, J; Sydes, M; Bielack, S; Sigbjorn, S; Marina, N; May, B; Butterfass-Bahloul, T; ... Bernstein, M; + view all (2008) Successful trans-Atlantic collaboration in a randomised controlled trial in osteosarcoma:EURAMOS1 (ISRCTN67613327; a trial conducted as part of ECT EUROCORES) - a potential model for collaboration in rare diseases. In:

Whelan, JS; McTiernan, A; Morgan, R; Sydes, MR; Souhami, RL; Bramwell, V; Lewis, I; ... Taminiau, A; + view all (2008) Mature results of 1067 patients treated in three European Osteosarcoma Intergroup randomised studies. In:

Wilkinson, SJ; Kucukmetin, A; Cross, P; Darby, S; Gnanapragasam, VJ; Calvert, AH; Robson, CN; (2008) Expression of gonadotrophin releasing hormone receptor I is a favorable prognostic factor in epithelial ovarian cancer. HUM PATHOL , 39 (8) 1197 - 1204. 10.1016/j.humpath.2007.12.011.

Wilson, RH; Plummer, R; Adam, J; Eatock, MM; Boddy, AV; Griffin, M; Miller, R; ... Calvert, H; + view all (2008) Phase I and pharmacokinetic study of NC-6004, a new platinum entity of cisplatin-conjugated polymer forming micelles. In: AMER SOC CLINICAL ONCOLOGY


Yang, W; Wetterskog, D; Matsumoto, Y; Funa, K; (2008) Kinetics of repression by modified p53 on the PDGF beta-receptor promoter. INTERNATIONAL JOURNAL OF CANCER , 123 (9) pp. 2020-2030. 10.1002/ijc.23735.

This list was generated on Sun Mar 18 01:51:07 2018 GMT.